Improving lung cancer treatment by targeting cell recycling processes
Targeting autophagy to increase the sensitivity of LKB1-deficient lung tumors to angiogenesis inhibitor
This study is looking at ways to make current treatments work better for people with non-small cell lung cancer who have certain genetic changes, by blocking a process that helps cancer cells survive, which could lead to improved results for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10669269 on NIH RePORTER |
What this research studies
This research investigates how to enhance the effectiveness of angiogenesis inhibitors in treating non-small cell lung cancer (NSCLC) patients with specific genetic mutations (KRAS and LKB1). The approach focuses on targeting autophagy, a cellular process that allows cancer cells to survive by recycling nutrients. By blocking this process, the research aims to make tumors more sensitive to existing treatments, potentially leading to better patient outcomes. The study will involve laboratory experiments and may include patient-derived samples to assess the effectiveness of this combined treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have mutations in both KRAS and LKB1.
Not a fit: Patients without these specific genetic mutations or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with aggressive lung cancer, potentially increasing survival rates.
How similar studies have performed: Previous research has shown promise in targeting autophagy to enhance cancer treatment, suggesting that this approach may lead to significant advancements in therapy.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Guo, Yanxiang — Rutgers Biomedical and Health Sciences
- Study coordinator: Guo, Yanxiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.